Ser574

Site Information
VGCFtPQsRRLRELP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 27996001

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , pancreatic ductal adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 3 ) , breast ( 1 , 2 ) , HeLa (cervical) ( 4 , 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
4	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
5	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info